Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,055Revenue (TTM) $M80.3Net Margin (%)-165.7Altman Z-Score-3.9
Enterprise Value $M958EPS (TTM) $-1.3Operating Margin %-170.8Piotroski F-Score--
P/E(ttm)--Beneish M-Score27.4Pre-tax Margin (%)-176.5Higher ROA y-yN
Price/Book13.510-y EBITDA Growth Rate %--Quick Ratio1.7Cash flow > EarningsN
Price/Sales13.15-y EBITDA Growth Rate %--Current Ratio1.7Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-32.0Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-100.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M106ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with LXRX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

LXRX is held by these investors:



LXRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Invus Public Equities, L.P.Director, 10% Owner 2017-11-17Buy180,727$10.11-1.19view
COATS LONNELPresident and CEO 2017-11-15Buy10,000$9.910.81view
WADE JEFFREY LEVP, Corp Adm Affairs and CFO 2017-11-14Buy2,000$9.485.38view
Invus Public Equities, L.P.Director, 10% Owner 2017-11-14Buy575,946$9.643.63view
COATS LONNELPresident and CEO 2017-09-15Buy30,000$12.54-20.33view
BARKER SAM LDirector 2017-09-15Buy1,000$12.5-20.08view
Tessmer James FVP, Finance & Accounting 2016-06-06Sell1,500$15-33.4view
Tessmer James FVP, Finance & Accounting 2016-05-23Sell6,000$13-23.15view
Invus C.V.Director, 10% Owner 2014-12-12Buy21,429$6.1662.18view
Invus C.V.Director, 10% Owner 2014-12-10Buy45,128$6.358.57view

Quarterly/Annual Reports about LXRX:

News about LXRX:

Articles On GuruFocus.com
Lexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan Financing Dec 05 2017 
Lexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan Financing Dec 05 2017 
New Research Coverage Highlights Principal Financial Group, Dunkin' Brands Group, Dell Technologies, Nov 17 2017 
Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides A Business Update Nov 08 2017 
Lexicon Pharmaceuticals To Host Third Quarter 2017 Financial Results Conference Call And Webcast On Nov 03 2017 
Lexicon Pharmaceuticals To Present At Upcoming Investor Conferences Nov 02 2017 
Lexicon Pharmaceuticals Initiates Patient Dosing In A Phase 1 Study Of LX9211 Sep 27 2017 
Weekly CEO Buys Highlights Sep 25 2017 
European Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome D Sep 19 2017 
Lexicon Pharmaceuticals To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference Sep 18 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK